 POINTs PNT6555 is a potent and specific inhibitor of Fibroblast Activation Protein FAP, a phase 1 therapeutic trial using 68 Ga-PNT6555 for imaging and 177 Lu-PNT6555 for therapy is planned for summer 2022 